Genomic Health, Inc. (GHDX) Scheduled to Post Earnings on Wednesday
Genomic Health, Inc. (NASDAQ:GHDX) will be releasing its earnings data after the market closes on Wednesday, November 8th. Analysts expect Genomic Health to post earnings of ($0.02) per share for the quarter.
Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The firm had revenue of $85.50 million during the quarter, compared to the consensus estimate of $86.08 million. During the same period last year, the business earned ($0.18) EPS. The business’s revenue was up 4.3% on a year-over-year basis. On average, analysts expect Genomic Health to post $-0.02 EPS for the current fiscal year and $0.36 EPS for the next fiscal year.
TRADEMARK VIOLATION WARNING: “Genomic Health, Inc. (GHDX) Scheduled to Post Earnings on Wednesday” was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/11/01/genomic-health-inc-ghdx-scheduled-to-post-earnings-on-wednesday.html.
GHDX has been the subject of several research reports. Canaccord Genuity reduced their price target on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Tuesday, August 15th. BidaskClub upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Piper Jaffray Companies reiterated a “hold” rating and set a $31.00 target price on shares of Genomic Health in a research report on Thursday, August 3rd. Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $33.00 price objective on shares of Genomic Health in a research report on Thursday, September 14th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $32.00.
In related news, insider James J. Vaughn sold 8,000 shares of Genomic Health stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $30.59, for a total value of $244,720.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Kimberly J. Popovits sold 5,000 shares of Genomic Health stock in a transaction on Monday, August 14th. The shares were sold at an average price of $30.22, for a total transaction of $151,100.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,000 shares of company stock worth $1,022,620. 46.20% of the stock is currently owned by company insiders.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.